OSE IMMUNOTHERAPEUTICS EUR0.20 financial statements, including revenue, expenses, profit, and loss

The total revenue of 0RAD for the last semiannual is 69.05 M EUR, and it's 7845.45% higher compared to the previous semiannual. The net income of H1 24 is 57.17 M EUR.